Cempaka Putri Desak Ketut Sekar, Andrianto Andrianto, Al-Farabi Makhyan Jibril, Saputra Pandit Bagus Tri, Nugraha Ricardo Adrian
Department of Cardiology and Vascular Medicine, Soetomo General Hospital, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.
Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.
Eur Cardiol. 2023 Jan 21;18:e02. doi: 10.15420/ecr.2022.10. eCollection 2023 Feb.
This article evaluates the efficacy of using ranolazine to improve diastolic performance and exercise capacity in heart failure with preserved ejection fraction. A comprehensive literature review found eight trials where there are no significant difference in peak O2 (p=0.09) and exercise duration (p=0.18) between ranolazine and placebo. The ranolazine group had significantly higher and better diastolic parameters compared to placebo, with a mean difference of 0.45 (95% CI [27.18-39.50]). There were no significant differences for haemodynamic parameters (blood pressure and heart rate) and electrocardiography (QT interval) between ranolazine and placebo. The review found that ranolazine has good wefficacy to improve diastolic performance among heart failure with preserved ejection fraction patients and it does not affect blood pressure, heart rate and rate of ventricular repolarisation (shortening of the QT interval).
本文评估了使用雷诺嗪改善射血分数保留的心力衰竭患者舒张功能和运动能力的疗效。一项全面的文献综述发现了八项试验，其中雷诺嗪组与安慰剂组在峰值氧耗量（p=0.09）和运动持续时间（p=0.18）方面无显著差异。与安慰剂相比，雷诺嗪组的舒张参数显著更高且更好，平均差异为0.45（95%置信区间[27.18 - 39.50]）。雷诺嗪组与安慰剂组在血流动力学参数（血压和心率）和心电图（QT间期）方面无显著差异。该综述发现，雷诺嗪在改善射血分数保留的心力衰竭患者舒张功能方面具有良好疗效，且不影响血压、心率和心室复极速率（QT间期缩短）。
